The Neo-ACT trial Newsletter, November 2023

Jana de Boniface, Cecilia Ringborg, Renske Altena, Yvonne Wengström and Marie Westman

Inclusion is up and running

Neo-ACT has randomized 57 patients in Sweden and Finland so far!

International expansion

The expansion of the trial to further international sites via different networks, e.g., EUBREAST (European Breast Cancer Research Association of Surgical Trialists) is ongoing. English-speaking and German-speaking countries will be the first in line to join the trial, potentially followed by further countries and languages in due course.

Translation of Vitala app into German The Vitala app is currently available in Swedish and English. The process to translate the Vitala app into German has been initiated.

Multiple German sites planned for participation from spring 2024

Once negotiations with the German Clinical Research Organization that will handle study administration and monitoring for Germanspeaking sites are completed, trial participation can be opened at German and German-speaking Swiss sites.



Vetenskapsrådet

Participation of sites in English-speaking countries

Hopefully, we can soon welcome sites in Scottland (Edinburgh and Glasgow), the UK (Royal Marsden), and Australia (Melbourne) to the trial. Discussions are ongoing regarding trial structure, logistics and set-up.

Exciting publication

The Journal of Clinical Oncology recently published the results of the LEANer study by Sanft et al, corroborating the hypothesis of exercise – here combined with a dietary intervention – improving pCR rates. In a randomized trial including 173 women with breast cancer, the secondary outcome pCR was 53% in those assigned to exercise and diet, as compared with 28% in those receiving usual care. A real boost for the Neo-ACT trial and a thumbs-up for our hypothesis!







January 2024.

Karolinska Department of Institutet Molecular Medicine and Surger MMK / Research / Breast Surgery / The Neo-ACT tria

The Neo-ACT trial eo-ACT trial is a randomized study to examine if a physical exercise vention during NACT can increase pCR rates in breast cancer

T Trial link to publication in PLoS P

Homepage


For any purposes and needs, please visit our trial homepage. https://ki.se/en/mmk/the-neo-act-trial

Contact: Trial management marie.westman@cytel.com





Patient reimbursement increased The site reimbursement per patient will increase to 600 Euro / 450 GBP from





Kind regards, The Neo-ACT Team

